Diversion of Methadone and Buprenorphine by Patients in Opioid Substitution Treatment in Sweden: Prevalence Estimates and Risk Factors

March 2, 2016

Dependence on heroin or other opiates is a condition which is difficult to treat. Research has been unable to point to any clear evidence of lasting effects of medication-free treatment. The dominant treatment method is opioid substitution treatment (OST) with methadone or buprenorphine, the latter often combined with naloxone. Metastudies show that OST is effective […]

Read the full article →

Analysis of ‘Revolving Door' Patients in Opioid Dependent Patients: the Impact of Treatment Discontinuation on Relapse Rates and Health Care Costs in us Public Health Insurance Claims

March 2, 2016

Buprenorphine/naloxone (BUP/NAL) combination is a well known treatment for opioid dependence. As a chronic relapsing disorder, some patients alternate between periods of on treatment and off treatment. The aim of this study was to compare health care resource utilization and costs between these patients and patients treated continuously. (Source: Value in Health)

Read the full article →

Comparison of Health Care Resource use and Costs in Patients with Opioid Prescription Drug Dependence (Opd) Treated with Buprenorphine/Naloxone and Patients without Pharmacological Treatment: Retrospective Analysis of us Public Insurance Claims

March 2, 2016

The objective of this study was to determine if there were health economic advantages related to treatment compared to no pharmacological treatment. (Source: Value in Health)

Read the full article →

Combined Abuse of Clonidine and Amitriptyline in a Patient on Buprenorphine Maintenance Treatment

March 2, 2016

Buprenorphine/naloxone maintenance therapy is often prescribed in primary care to treat opioid dependence. Previous reports have described concomitant abuse of opioids and clonidine. In this case, a primary care patient on buprenorphine/naloxone maintenance therapy demonstrating altered mental status, hallucinations, falls, and rebound hypertension was found to be concomitantly abusing clonidine and amitryptyline, which share metabolic […]

Read the full article →

Group Medication Management for Buprenorphine/Naloxone in Opioid-Dependent Veterans

March 2, 2016

Conclusions:This study found that veterans prescribed buprenorphine/naloxone in a group setting as part of a drug and alcohol treatment program were retained in treatment longer than veterans prescribed this medication individually. Because of inherent limitations in the study design, no causality can be determined; however, given the results found here, group medication management of buprenorphine/naloxone […]

Read the full article →

Effect of Steady-State Faldaprevir on the Pharmacokinetics of Steady-State Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy.

March 2, 2016

In conclusion, faldaprevir 240 mg QD can be coadministered with methadone or buprenorphine/naloxone without dose adjustment, although given the relatively narrow therapeutic windows of these agents, monitoring for opiate overdose and withdrawal may still be appropriate Registered at ClinicalTrials.gov registration number: NCT01637922. PMID: 25385094 [PubMed – as supplied by publisher] (Source: Antimicrobial Agents and Chemotherapy) […]

Read the full article →

Complete Care Medical Center Now Offering Outpatient Detox Treatment…

March 2, 2016

Complete Care Medical Center is now offering outpatient detox treatment with several Certified Suboxone Doctors in South Florida. The treatment is highly effective for those suffering from addiction…(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctors/south-florida/prweb12317157.htm (Source: PRWeb: Medical Pharmaceuticals)

Read the full article →

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk?

March 2, 2016

Authors: Soyka M Abstract Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particularly the case in the United States, where the number of related emergency visits is increasing, especially in children. […]

Read the full article →

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

March 2, 2016

Authors: Yokell MA, Zaller ND, Green TC, Rich JD Abstract The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and […]

Read the full article →

Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.

March 2, 2016

CONCLUSIONS: The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2014;XX:XX-XX). PMID: 25409987 [PubMed – as supplied by publisher] (Source: American […]

Read the full article →

← Previous Entries

Next Entries →